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Abstract
Aims/hypothesis Type 2 diabetes mellitus is associated with
reduced incretin effects. Although previous studies have
shown that hyperglycaemia contributes to impaired incretin
responses in beta cells, it is largely unknown how hyper-
lipidaemia, another feature of type 2 diabetes, contributes to
impaired glucagon-like peptide 1 (GLP-1) response. Here,
we investigated the effects of NEFA on incretin receptor
signalling and examined the glucose-lowering efficacy of
incretin-based drugs in combination with the lipid-lowering
agent bezafibrate.
Methods We used db/db mice to examine the in vivo effi-
cacy of the treatment. Beta cell lines and mouse islets were
used to examine GLP-1 and glucose-dependent insulino-
tropic peptide receptor signalling.
Results Palmitate treatment decreased Glp1r expression in
rodent insulinoma cell lines and isolated islets. This was
associated with impairment of the following: GLP-1-
stimulated cAMP production, phosphorylation of cAMP-
responsive elements binding protein (CREB) and insulin
secretion. In insulinoma cell lines, the expression of exog-
enous Glp1r restored cAMP production and the phosphor-
ylation of CREB. Treatment with bezafibrate in combination
with des-fluoro-sitagliptin or exendin-4 led to more robust
glycaemic control, associated with improved islet morphol-
ogy and beta cell mass in db/db mice.
Conclusions/interpretation Elevated NEFA contributes to
impaired responsiveness to GLP-1, partially through down-
regulation of GLP-1 receptor signalling. Improvements in
lipid control in mouse models of obesity and diabetes increase
the efficacy of incretin-based therapy.
Keywords Dipeptidyl peptidase-4 . Exendin-4 . Glucagon-
like peptide 1 . Glucose-dependent insulinotropic
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Introduction
The gastrointestinal hormones, glucagon-like peptide 1
(GLP-1) and glucose-dependent insulinotropic polypeptide
(GIP), cause glucose-dependent insulin secretion from pan-
creatic beta cells within minutes of nutrient ingestion [1, 2].
One characteristic of type 2 diabetes mellitus is impaired
incretin effect [3, 4], although the secretion of GIP and
GLP-1 is not always decreased [4–6]. This indicates that
the reduced incretin effect is due to defects in incretin
receptor signalling pathways, rather than to the concentra-
tion of incretin hormones. The insulinotropic activity of GIP
is largely impaired in patients with type 2 diabetes [4, 7]. In
contrast, the insulinotropic effects of GLP-1 are partially
preserved, which is important for its therapeutic potential,
but insulin responses are substantially reduced, especially
when studies are done at comparable glucose levels [7, 8].
Moreover, a growing body of evidence has shown that the
glucose-lowering effects of GLP-1 are mediated by various
mechanisms, including stimulation of glucose-dependent in-
sulin secretion in pancreatic beta cells [1, 2], promotion of
pancreatic beta cell proliferation and inhibition of beta cell
apoptosis [9–11], inhibition of pancreatic alpha cell glucagon
release [12, 13] and regulation of appetite and the central
nervous system [2, 14]. These attributes of GLP-1 provide a
strong basis for novel pharmacotherapies in type 2 diabetes.
Currently, synthetic versions of GLP-1 mimetics (e.g. exena-
tide and liraglutide) and dipeptidyl peptidase-4 (DPP-4) inhib-
itors (e.g. sitagliptin and vildagliptin), which reduce GLP-1
and GIP degradation by DPP-4, have been approved for the
treatment of type 2 diabetes [2, 15].
Type 2 diabetes develops as a result of impaired beta cell
function and is closely associated with increased plasmaNEFA,
which are thought to be an important link between obesity and
type 2 diabetes [16–18]. NEFA can result in a state of insulin
resistance [19], induce pancreatic beta cell dysfunction and
cause beta cell death [18, 20]. Although acute exposure to
elevated plasma NEFA enhances glucose- and non-glucose-
stimulated insulin secretion in vitro and in vivo [18, 21], long-
term exposure to NEFA impairs glucose-stimulated insulin
secretion [22]. Recently, it was reported that while incretin
secretion is similar between obese and non-obese type 2 dia-
betic patients [23], obesity impairs the incretin effect
independently of glucose tolerance [24]. It has also been
reported that loss of the incretin effects was more extensive in
obese than in lean type 2 diabetic patients [25]. More recently,
Bando et al reported that obesity may attenuate the HbA1c-
lowering effect of sitagliptin in Japanese type 2 diabetic patients
[26]. This suggests that lipids may be involved in the regulation
of incretin responsiveness in pancreatic beta cells. However,
little is known about the influence of NEFA on incretin receptor
signalling. Our previous study showed that hyperglycaemia
downregulates GLP-1 receptor (GLP1R), which potentially
contributes to the impaired incretin response in beta cells [27].
Furthermore, the normalisation of blood glucose concentrations
improves the insulin response to GLP-1 and GIP in patients
with type 2 diabetes [28]. In the present study, therefore, we
used in vitro and in vivo approaches to investigate the role of
NEFA in the impairment of incretin responses.
Methods
Chemicals and reagents For details, see electronic supple-
mentary material (ESM), Chemicals and reagents.
Cell culture and treatment INS-1E cell line (passages 65 to
75) was a kind gift from P. Maechler (Department of Cell
Physiology and Metabolism, University of Geneva, Geneva,
Switzerland). INS-1E and MIN6 cells were grown as de-
scribed previously [11, 29]. Cells were cultured in 6- or 12-
well plates for 24 to 48 h before treatment with palmitate or
1.05% (wt/vol) BSA (in RPMI 1640 or DMEM with 1%
FBS). GLP-1, GIP, exendin-4 and [D-Ala2]GIP(1-30) (D-
GIP) were dissolved in PBS and stored at −80°C. To achieve
expression of exogenous Glp1r, cells were infected with an
adenoviral vector (Ad), Ad-GLP1R, for 6 h prior to treat-
ment with palmitate or 1.05% BSA.
Islet isolation and culture, construction of Ad-GLP1R, RT-
PCR, western blotting and measurement of cAMP produc-
tion, and insulin secretion Pancreatic islets were isolated
from 8- to 9-week-old male C57BL/6J mice as previously
described (ESM Methods, Isolation and cell culture). The
gateway-compatible adenoviral expression system was used
to generate the recombinant adenoviruses (ESM Methods,
Construction of Ad-GLPR1). Real-time PCR (ESMMethods,
RNA extraction and quantitative RT-PCR) and western blot-
ting (ESM Methods, Analysis of phosphorylation of CREB)
were performed with standard procedures. Intracellular cAMP
content was determined using a kit (Cyclic AMP EIA; Cay-
man, Ann Arbor, MI, USA) (ESMMethods, Measurement of
cAMP production) and protein levels were assayed by BCA
for the correction. Insulin secretion was measured in INS1-E
cells ormouse islets after exposure to 3 or 16.7mmol/l glucose
(ESM Methods, Measurement of insulin secretion).
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Animals and experimental protocols All animal procedures
were performed in accordance with the Guidelines for Care and
Use of Laboratory Animals and approved by The Animal
Subjects Committee of The Chinese University of Hong Kong.
Male db/db and db/+ (control) mice (aged 7 to 8 weeks) were
obtained from The Chinese University of Hong Kong and
housed in specific pathogen-free conditions with a 12 h light–
dark cycle and free access to water and food. Experiments were
performed after 1 week of acclimatisation. For drug treatments,
des-fluoro-sitagliptin (200 mg/kg) and bezafibrate (100 mg/kg)
were dissolved in 0.5% (wt/vol) CMC and given by gavage;
exendin-4 (10 nmol/kg) and D-GIP (24 nmol/kg) were dis-
solved in PBS and given by intraperitoneal injection. Mice
were treated daily (16:00 to 18:00 hours) by gavage or intra-
peritoneal injection for the indicated time. Fed random blood
glucose was monitored weekly at 09:00 to 10:00 hours. For
measurement of the acute glucose-lowering actions of exendin-
4 and D-GIP, db/db mice were treated with vehicle or bezafi-
brate for 2 weeks and then injected intraperitoneally with
saline, exendin-4 or D-GIP. Glucose levels were determined at
0, 30, 60 and 240 min after injection.
OGTT, insulin tolerance test and serum lipid profile meas-
urement For the OGTT, mice were fasted overnight (~17 h).
Glucose levels were determined using a glucometer
(Johnson & Johnson, Milpitas, CA, USA) at 0, 30, 60 and
120 min after oral administration of 0.3 g/kg glucose. For the
insulin tolerance test (ITT), done after 6 h of fasting, mice
were intraperitoneally injected with 2 IU/kg human insulin
(Novo Nordisk, Bagsvaerd, Denmark). Glucose levels were
measured at 0, 30, 60 and 120 min after the injection.
Triacylglycerol, NEFA and total cholesterol concentrations
were measured using related kits (Wako Lab Assays, Rich-
mond, VA, USA). HDL-cholesterol was determined by en-
zymatic assays using an automated analyser (Olympus,
Tokyo, Japan).
Histological analysis Pancreases were quickly dissected
from mice and fixed in 4% (wt/vol.) paraformaldehyde, after
which paraffin-embedded 4-μm sections were immuno-
stained overnight at 4°C with guinea pig anti-insulin (Dako,
Glostrup, Denmark) and mouse anti-glucagon (1:200; Ac-
curate Chemical & Scientific, Westbury, NY, USA), or with
mouse anti-BrdU (BD Biosciences, Franklin Lakes, NJ,
USA) antibodies. Following this, staining with cy2-goat
anti-guinea pig or cy3-donkey anti-mouse (1:400; Jackson,
West Grove, PA, USA) was done at room temperature for
2 h. The sample slides were washed three times with 0.1%
PBS Tween (vol./vol., PBST) and stained with DAPI (Invi-
trogen, Grand Island, NY, USA) before microscopic analy-
sis. The insulin-positive area vs total pancreas or total islet
area was evaluated using Image J (NIH, Bethesda, Mary-
land, USA) [10].
Statistical analysis Animal data are expressed as means ±
SEM. Differences between the groups were examined for
statistical significance using one-way or two-way ANOVA,
followed by Dunnett’s post tests or t tests (as appropriate). For
in vitro experiments, quantitative RT-PCR data are expressed
as means ± SEM; other data are presented as means ± SD.
Statistical significance was determined by Student’s t test. A
value of p<0.05 was considered to be statistically significant.
Results
Reduced expression of Glp1r and reduction of GLP-1-
stimulated insulin secretion in palmitate-treated beta cells
and mouse islets In rat INS-1E cells, palmitate treatment
significantly reduced Glp1r mRNA expression and levels of
GLP1R in a dose-dependent manner (Fig. 1a, ESM Fig. 1a,
c), while no effect on Gipr mRNA expression was observed
(Fig. 1a). Similar results were found in mouse MIN6 cells
(Fig. 1b, ESM Fig. 1b, d). Consistent with these results,
exposure to palmitate also led to decreases in Glp1r mRNA
expression in isolated islets (Fig. 1c). We next examined
transcription factor 7-like 2 (TCF7L2), which has been
reported to regulate the expression of Glp1r and Gipr in
beta cells [30]. However, Tcf7l2 mRNA expression was not
changed by palmitate treatment in INS-1E or MIN6 cells
(Fig. 1a, b). Similarly, Irs2 mRNA was not affected by
palmitate (Fig. 1a, b). Upregulation of uncoupling protein-
2 (UCP2) and sterol regulatory element binding protein 1c
(SREBP1c) is known to play a crucial role in NEFA-
induced beta cell dysfunction [31]. As expected, the mRNA
expression of Ucp2 and Srebp1c (also known as Srebf1) was
significantly increased by palmitate in INS-1E cells
(Fig. 1a). However, in MIN6 cells, Ucp2 was upregulated
while Srebp1c was unchanged by palmitate (Fig. 1b).
In islets isolated from db/db mice, we also found that
Glp1r and Gipr mRNA were significantly reduced com-
pared with expression in control mice (Fig. 1d, e). Interest-
ingly, db/db mice that were treated with the lipid-lowering
agent bezafibrate for 2 weeks displayed partial restoration of
Glp1r and Gipr mRNA to levels not different from control
mice (Fig. 1d, e), with lowered triacylglycerol and NEFA,
but no obvious changes in glucose levels [32].
To further assess the functional consequences of the reduc-
tions in Glp1r and Gipr expression, we assayed insulin se-
cretion in INS-1E cells and isolated islets. In INS-1E control
cells, both GLP1R agonists (GLP-1, exendin-4) and the GIP
receptor (GIPR) agonists (GIP, D-GIP) markedly increased
insulin secretion in the presence of 16.7 mmol/l glucose
(Fig. 1f). However, after pre-incubation with palmitate, this
response was significantly attenuated (Fig. 1f). Similar
results were found in isolated mouse islets, with palmitate
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treatment decreasing the fold induction of GLP-1-stimulated
glucose-dependent insulin secretion (Fig. 1g).
Palmitate impairs GLP-1-stimulated cAMP production and
phosphorylation of cAMP-responsive elements binding pro-
tein in rodent insulinoma cell lines GLP-1 and GIP exert
their effects by binding to their respective receptors, GLP1R
and GIPR, leading to activation of adenylate cyclase and
elevation of intracellular cAMP. In INS-1E cells, palmitate
treatment decreased GLP-1- and GIP-stimulated cAMP pro-
duction (Fig. 2a), while in MIN6 cells, GLP-1- but not GIP-
stimulated cAMP production was reduced by palmitate
(Fig. 2b). We then examined cAMP-responsive elements
binding protein (CREB) phosphorylation (p-CREB), as
CREB is an important transcription factor in glucose
homeostasis and beta cell survival [33]. In INS-1E cells,
palmitate treatment significantly reduced GLP-1-stimulated
p-CREB in a time- and dose-dependent manner (Fig. 2c, e).
In contrast, GIP-stimulated p-CREB was unchanged
throughout the time course of activation (Fig. 2c, f). Simi-
larly, in MIN6 cells, palmitate treatment decreased GLP-1-
but not GIP-stimulated p-CREB (Fig. 2d).
Expression of exogenous Glp1r restores GLP-1-stimulated
cAMP production and p-CREB in palmitate-treated rodent
insulinoma cell lines As GLP1R signalling is crucial for
glucose homeostasis, we examined whether the expression
of exogenous Glp1r could reverse the impairment of
GLP1R signalling by palmitate. We constructed and
expressed adenoviral vectors expressing mouse Glp1r (Ad-
Fig. 1 Glp1r mRNA expression and GLP-1-stimulated insulin secre-
tion are reduced in palmitate-treated rodent insulinoma cell lines and
mouse islets. (a) INS-1E or (b) MIN6 cells were treated for 24 h with
1.05% BSA (grey bars) or palmitate (INS-1E 0.8 mmol/l, MIN6
0.4 mmol/l) (black bars), and the relative mRNA expression of genes
as indicated was quantified by quantitative RT-PCR. β-Actin mRNA
was used as control. Data were normalised to those for cells treated
with BSA; n04–6; *p<0.05, **p<0.01 and ***p<0.001 for palmitate-
vs BSA-treated. (c) Mouse islets were treated for 48 h with 1.05% BSA
or 0.4 mmol/l palmitate, and the relative mRNA expression of Glp1r
and Gipr was quantified by quantitative RT-PCR. Data were normal-
ised to those for islets treated with BSA; n05; *p<0.05 vs BSA-treated
islets. (d, e) db/db mice were treated for 2 weeks with bezafibrate
(Beza) (0.2% of food) and the relative mRNA expression of (d) Glp1r
and (e) Gipr in islets from control (db/+), untreated db/db and
bezafibrate-treated db/db mice was quantified; n03–8 for each exper-
imental group; **p<0.01 vs islets from control. (f) INS-1E cells and
(g) isolated islets were treated with 1.05% BSA or palmitate (INS-1E
0.8 mmol/l, islets 0.4 mmol/l) for 24 and 48 h, respectively. Glucose-
stimulated insulin secretion was measured (f) in the presence of PBS,
GLP-1 (100 nmol/l), exendin-4 (Ex-4; 100 nmol/l), GIP (100 nmol/l)
or D-GIP (100 nmol/l) as described, and (g) as fold changes relative to
the corresponding low-glucose (3 mmol/l) controls; n03–5; *p<0.05,
**p<0.01 and ***p<0.001 vs corresponding BSA-treated controls
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GLP1R) in INS-1E and MIN6 cells. Our RT-PCR results
show that mouse Glp1r was expressed in rat INS-1E cells
after infection with Ad-GLP1R (ESM Fig. 2). Functionally,
INS-1E cells infected with Ad-GLP1R also showed
increases in basal levels of GLP-1-stimulated cAMP pro-
duction compared with cells infected with a control Ad with
green fluorescent protein (GFP) (Ad-GFP) (Fig. 3a). This
result indicated enhanced GLP1R signalling. Palmitate
treatment resulted in reduced GLP-1-stimulated cAMP pro-
duction in INS-1E cells infected with Ad-GFP or Ad-
GLP1R (Fig. 3a). However, Ad-GLP1R-mediated expres-
sion of exogenous Glp1r still restored GLP-1-stimulated
cAMP production to the normal level in the presence of
palmitate (Fig. 3a). Expression of exogenous Glp1r also
restored GLP-1-stimulated p-CREB to the normal level in
the presence of palmitate (Fig. 3c). Similarly, in MIN6 cells,
infection with Ad-GLP1R protected against the palmitate-
mediated reductions of GLP-1-stimulated cAMP production
and p-CREB (Fig. 3b, d). To summarise, the above data
suggest that the impairment of GLP-1-stimulated cAMP
production and p-CREB in rodent insulinoma cell lines by
palmitate can be at least partially restored by the expression
of exogenous Glp1r.
Lipid lowering enhances the efficacy of the DPP-4 inhibitor,
des-fluoro-sitagliptin, in db/db mice Since our findings im-
plicate increased fatty acids in the impairment of GLP1R
signalling through downregulation of GLP1R, we next in-
vestigated whether an improvement in the lipid profile
would enhance responsiveness to incretin hormones in
mouse models of diabetes. We first used the DPP-4 inhibi-
tor, des-fluoro-sitagliptin, combined with the lipid-lowering
drug, bezafibrate, in db/db mice. Administration of des-
fluoro-sitagliptin or bezafibrate alone had no effect on blood
glucose levels during the 8 week treatment period compared
with the vehicle-treated control group (Fig. 4a, b). In
Fig. 2 Palmitate impairs GLP-1-stimulated cAMP production and
phosphorylation of CREB in rodent insulinoma cell lines. (a, c, e, f)
INS-1E or (b, d) MIN6 cells were treated with 1.05% BSA (grey bars
[a, b, c, d, e, f]) or palmitate (Pa); black bars 0.8 mmol/l [a, c, e, f],
0.4 mmol/l [b, d]; dark grey bars 0.4 mmol/l [c], 0.2 mmol/l [d] for
24 h) and stimulated with PBS, 100 nmol/l GLP-1 or 100 nmol/l GIP,
after which (a, b) total cAMP, and (c, d) the dose- and (e, f) time-
dependent phosphorylation of CREB (p-CREB) were assessed. Total
cAMP (a, b) was measured as described (ESMMethods, Measurement of
cAMP production) after cells had been stimulated for 10 min in medium
containing 500 μmol/l IBMX, in the presence of PBS, 100 nmol/l GLP-1
or 100 nmol/l GIP. (c, d) p-CREBwas analysed bywestern blot after cells
had been stimulated with PBS, 100 nmol/l GLP-1 or 100 nmol/l GIP for
15 min or (e, f) for the indicated times. Intensities were quantified,
normalised against the level of actin and expressed as per cent of protein
abundance in corresponding BSA-treated cells. Results shown are repre-
sentative of three independent experiments; *p<0.05, **p<0.01 and
***p<0.001 vs corresponding BSA-treated cells
Fig. 3 Expression of exogenous Glp1r reversed the palmitate-induced
impairment of GLP-1-stimulated cAMP production and p-CREB in
rodent insulinoma cell lines. (a, c) INS-1E or (b, d) MIN6 cells were
infected overnight with Ad-GFP and Ad-GLP1R, and then treated for
24 h with 1.05% BSA or 0.8 mmol/l palmitate (Pa). Total cAMP (a, b)
and p-CREB (c, d) were assessed as for Fig. 2. The intensity of western
blots was quantified, normalised against the level of actin and
expressed as percentages of protein abundance in the corresponding
BSA-treated and GFP-infected cells. Results are representative of three
independent experiments; *p<0.05, **p<0.01 and ***p<0.001 for
palmitate vs corresponding BSA-treated cells; †p<0.05 for Ad-
GLP1R vs GFP-infected cells treated with BSA
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contrast, treatment with des-fluoro-sitagliptin and bezafi-
brate together significantly decreased blood glucose levels
from 3 weeks onwards until the end of the experiment
(Fig. 4a, b). We next examined the effects of these treat-
ments on glucose tolerance by performing OGTTs. Glucose
tolerance in db/db mice was not affected by 6 weeks of
treatment with des-fluoro-sitagliptin or bezafibrate alone
(Fig. 4c, d). However, treatment with des-fluoro-sitagliptin
and bezafibrate combined significantly improved glucose
excursions during the OGTT compared with the vehicle
control group (Fig. 4c, d). This was not due to changes in
insulin sensitivity, as there was no difference in the blood
glucose response between the treatment groups during the
ITT (Fig. 4e, f). The lipid-lowering effects of bezafibrate
were confirmed by measuring circulating triacylglycerol and
NEFA concentrations. As expected, serum triacylglycerol and
NEFAwere significantly decreased after bezafibrate and com-
bined des-fluoro-sitagliptin and bezafibrate treatments (ESM
Fig. 3). In addition, HDL and total cholesterol levels were
elevated in the bezafibrate and combined des-fluoro-
sitagliptin and bezafibrate groups (ESM Fig. 3).
Pancreatic beta cells are important targets of incretin-based
drugs. We analysed the islet morphology and beta cell mass of
db/db mice after the various drug treatments. As shown in
Fig. 5a, the normal islet architecture of control mice com-
prised a large core of insulin-positive beta cells ringed by a
mantle of glucagon-positive alpha cells. In contrast, islets of
vehicle-treated db/db mice exhibited an abnormal architec-
ture, with reduced beta cells and increased alpha cells that
were scattered throughout the islet core (Fig. 5a). A similar
abnormal islet morphology was observed in db/db mice that
were treated with des-fluoro-sitagliptin or bezafibrate alone
(Fig. 5a). Only mice treated with a combination of des-fluoro-
sitagliptin and bezafibrate displayed an improved islet archi-
tecture approaching that of normal islets, as evidenced by
increased beta cell mass (measured as beta cell area per
pancreas area) (Fig. 5b), an increased proportion of beta cells
per islet (Fig. 5c) and the appearance of normal beta cell
distribution within the islets (Fig. 5a).
Lipid lowering enhances the efficacy of an agonist to
GLP1R (exendin-4) but not to GIPR (D-GIP) in db/db
mice DPP-4 inhibition prevents the degradation of GLP-1
and GIP, resulting in increased levels of biologically active
GLP-1 and GIP in vivo. To investigate the effects of lipid
lowering on the activity of each incretin separately, we
tested the efficacy of the GLP1R agonist, exendin-4, or the
Fig. 4 Lipid lowering enhances the efficacy of the DPP-4 inhibitor
des-fluoro-sitagliptin to improve glucose tolerance in db/db mice. Mice
(db/db) were orally treated with des-fluoro-sitagliptin or bezafibrate
alone, or with sitagliptin and bezafibrate combined. Treatment was
once a day for 8 weeks. (a, b) Random fed blood glucose levels, and
results of (c, d) an OGTT (after 6 weeks of treatment) and (e, f) an ITT
(after 7 weeks of treatment) are shown. n05–8 for each experimental
group; *p<0.05 and ***p<0.01 compared with vehicle group. Key: (a,
c) black diamonds, control; black circles, vehicle; black squares, des-
fluoro-sitagliptin; upright triangles (grey), bezafibrate; reversed trian-
gles (grey), des-fluoro-sitagliptin plus bezafibrate; (e) black circles,
vehicle; black squares, des-fluoro-sitagliptin; upright triangles (grey),
bezafibrate; reversed triangles (grey), des-fluoro-sitagliptin plus
bezafibrate
Fig. 5 Immunohistochemical analysis of the pancreas of db/db mice
after co-treatment with the DPP-4 inhibitor des-fluoro-sitagliptin and
bezafibrate. Mice (db/db) were orally treated with des-fluoro-sitagliptin
(Sitag) or bezafibrate (Beza) alone, or with sitagliptin and bezafibrate
combined (Sita + Beza). Treatment was once a day for 8 weeks. (a)
Representative images of immunofluorescence analysis of islets
stained for insulin (green), glucagon (red) and DAPI (blue). (b) Beta
cell mass expressed as the percentage of insulin-positive area to total
pancreas area and (c) ratios of insulin-positive beta cell area to total
islet area were assessed from the staining for insulin and glucagon in
images (a). n07–12 for each experimental group; *p<0.05 and ***p<
0.001 compared with vehicle groups
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GIPR agonist, D-GIP, either alone or in combination with
bezafibrate, in db/db mice. First, db/db mice were treated
with vehicle or bezafibrate for 2 weeks. As expected, these
treatments significantly reduced plasma triacylglycerol and
NEFA levels (data not show) without changes in blood
glucose levels (Fig. 6c, d). We then assessed the glucose-
lowering effect of acute GLP1R or GIPR activation after an
intraperitoneal injection of a single dose of exendin-4
(1 nmol/kg) or D-GIP (24 nmol/kg). Acute treatment of db/
db mice with exendin-4 significantly lowered blood glucose
to a similar level to that in vehicle- and bezafibrate-treated
groups compared with PBS injection (Fig. 6a). In contrast,
the administration of D-GIP did not affect the hyperglycae-
mic status in either vehicle- or bezafibrate-treated db/db
mice (Fig. 6b). Following the acute glucose-lowering exper-
iments, the mice were treated with exendin-4 or D-GIP for
an additional 3 weeks as described in the Methods. Under
these chronic experimental conditions, neither exendin-4
nor D-GIP administration alone altered blood glucose levels
(Fig. 6c, d). In mice treated with exendin-4 and bezafibrate
combined, fed blood glucose levels were significantly re-
duced after 1 week and for the remainder of the treatment
period (Fig. 6c). In contrast, treatment with D-GIP and
bezafibrate combined did not affect blood glucose levels
(Fig. 6d). In response to the OGTT only the group treated
with exendin-4 and bezafibrate combined exhibited signifi-
cantly improved glucose tolerance (Fig. 6e). In contrast, D-
GIP slightly worsened glucose excursions during the OGTT
and combined treatment with D-GIP and bezafibrate did not
improve glucose tolerance (Fig. 6f). Chronic treatment of
db/db mice with bezafibrate, exendin-4 or exendin-4 and
bezafibrate combined did not alter insulin sensitivity, as
indicated by the unchanged blood glucose levels compared
with the vehicle control group during the ITT (ESM
Fig. 4a). On the other hand, in mice treated with D-GIP or
D-GIP and bezafibrate combined, the AUC for blood glu-
cose levels during the ITT was slightly, but significantly
elevated, indicating a modest impairment of insulin action
(ESM Fig. 4b). As expected, exendin-4 or D-GIP treatments
had no effects on serum triacylglycerol, NEFA and HDL-
Fig. 6 Lipid lowering enhances the efficacy of exendin-4 (1 nmol/l),
but not of D-GIP (24 nmol/l) in db/db mice. (a) The acute glucose-
lowering effects of exendin-4 (Ex-4) or (b) D-GIP were assessed in db/
db mice that had been orally treated with bezafibrate (Beza) or vehicle
for 2 weeks. (a) Black circles, vehicle + PBS; grey squares, vehicle +
Ex-4; grey triangles, Beza + Ex-4; (b) black circles, vehicle + PBS;
grey squares, vehicle + D-GIP; grey triangles Beza + D-GIP. Following
the pretreatment period, db/db mice were treated with additional
exendin-4 (c) or D-GIP (d) for 3 weeks and random fed blood glucose
levels measured once a week. (c) Black circles, vehicle; black squares,
Ex-4; upright triangles (grey), Beza; reversed triangles (grey), Ex-4 +
Beza; (d) black circles, vehicle; black squares, D-GIP; upright triangles
(grey), Beza; reversed triangles (grey), D-GIP + Beza. (e) OGTTs were
performed in the Ex-4-Beza or (f) D-GIP-Beza groups after 2 weeks of
co-treatment with bezafibrate and either exendin-4 or D-GIP. (e) Black
circles, vehicle; black squares, Ex-4; upright triangles (grey), Beza;
reversed triangles (grey), Ex-4 + Beza; (f) Black circles, vehicle; black
squares, D-GIP; upright triangles (grey), Beza; reversed triangles
(grey), D-GIP + Beza n05–8 for each group; *p<0.05, **p<0.01 and
***p<0.001 compared with vehicle groups
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cholesterol levels, while bezafibrate alone or in combination
with exendin-4 or D-GIP lowered serum triacylglycerol and
NEFA levels, and increased serum total- and HDL-
cholesterol levels (ESM Fig. 5).
Finally, we analysed the islet morphology of db/db mice
after the various treatments using immunohistochemistry.
As seen in Fig. 7a, islets from bezafibrate-, exendin-4- or
D-GIP-treated db/db mice displayed a disordered islet mor-
phology, which was similar to that in vehicle-treated db/db
mice. Similarly, db/db mice treated with a combination of D-
GIP and bezafibrate did not show any improvements in islet
architecture compared with the vehicle group (Fig. 7a).
However, mice treated with a combination of exendin-4
and bezafibrate displayed normalised islet architecture, with
an increased proportion of beta cells, as well as normal
distribution of alpha cells (Fig. 7a). Furthermore, only the
exendin-4 plus bezafibrate group exhibited significantly
increased beta cell mass and ratios of beta cell area to islet
area compared with the vehicle-treated group (Fig. 7b, c).
BrdU staining also showed that only the exendin-4 plus
bezafibrate group significantly increased the number of
BrdU-positive beta cells in islets compared with the
vehicle-treated group (Fig. 7d, e). These data indicate that
lipid lowering selectively enhanced the efficacy of GLP1R
but not GIPR agonists to improve islet morphology and
glucose homeostasis, possibly through increases in pancre-
atic beta cell proliferation in db/db mice.
Discussion
Impaired incretin effects are found in type 2 diabetes [3, 4].
Our study was designed to investigate the role of hyperlipi-
daemia in the impairment of the incretin response in vitro and
in vivo. In the in vitro models, we found that exposure to
palmitate was sufficient for impairment of GLP1R, but not
GIPR signalling to occur. This was evidenced by a reduced
ability of GLP-1 to stimulate cAMP production, p-CREB and
insulin secretion. The specificity of these defects was demon-
strated by the partial restoration of signalling after Ad-
GLP1R-mediated expression of exogenous Glp1r. In the in
vivomodels, we found that hyperlipidaemia was necessary for
the downregulation of incretin receptor expression in islets of
a mouse model of diabetes. Furthermore, in the db/db mouse
model of diabetes, normalisation of the lipid profile by beza-
fibrate dramatically improved the efficacy of incretin-based
therapies, including the DPP-4 inhibitor, des-fluoro-
Fig. 7 Immunohistochemical analysis of the pancreas of db/db mice
co-treated with bezafibrate (Beza) and either exendin-4 (Ex-4) or
D-GIP. db/db mice were treated as in Fig. 7. (a) Pancreas was fixed
in 4% paraformaldehyde and paraffin-embedded 4 μm sections sub-
jected to immunofluorescence analysis. Green, insulin; red, glucagon;
blue, DAPI. (b) Beta cell mass expressed as the percentage of insulin-
positive area to total pancreas area and (c) ratios of insulin-positive
beta cell area to total islet area were assessed from staining (a) for
insulin and glucagon; n05–8 each group; **p<0.01 and ***p<0.001
compared with vehicle group. (d, e) Mice (db/db) were pretreated for
2 weeks with either bezafibrate or vehicle, and then treated with
additional exendin-4 and BrdU (1 g/l in drinking water) for 10 days.
Representative images (d) of pancreas sections stained for BrdU (red)
and insulin (green) are shown. (e) BrdU-positive beta cells were
quantified and expressed as percentage of respective islet beta cells;
n03–4 each group; *p<0.05 compared with vehicle group
430 Diabetologia (2013) 56:423–433
sitagliptin, and the GLP1R agonist, exendin-4. These find-
ings, together with the work of others [34], indicate crucial
roles of fatty acids and GLP1R in maintaining incretin signal-
ling, beta cell function and glucose homeostasis.
We and others have reported that GLP1R and GIPR levels
were decreased in islets from mouse and rat models of diabe-
tes, and from type 2 diabetic patients [27, 30, 35]. In the
present study, we found that in vitro palmitate treatment
resulted in reduced GLP1R levels. In islets isolated from db/
db mice, we also observed a significant reduction of Glp1r
expression. Furthermore, treatment of db/db mice with beza-
fibrate for 2 weeks, which significantly improved the serum
lipid profile, partially restoredGlp1r expression in islets, even
though the hyperglycaemic status remained. These findings
imply that, apart from hyperglycaemia, hyperlipidaemia is
required for downregulation of Glp1r expression in diabetes.
GIPR was less sensitive to regulation by palmitate. This
difference in the regulation of incretin receptors by fatty acids
is reminiscent of the effects of hyperglycaemia; thus conscious
rats receiving glucose infusions and isolated rat islets exposed
to high glucose exhibited decreases in Glp1r but not Gipr
expression [27]. Although Gipr expression was unaltered in
palmitate-treated INS-1E cells, GIP-stimulated cAMP pro-
duction and insulin secretion were significantly decreased.
This discrepancy in findings for GIP is possibly due to
NEFA-induced global beta cell dysfunction via other path-
ways involving endoplasmic reticulum stress, oxidative stress
and Ca2+ homeostasis [29, 31]. For example, SREBP1c,
which was reported to mediate palmitate-induced impairment
of insulin secretion in islets [36], was increased in INS-1E, but
not in MIN6 cells after palmitate treatment. The results prob-
ably reflect the complexity of the effects of hyperlipidaemia
on beta cell function, with impaired incretin receptor signal-
ling contributing to beta cell glucolipotoxicity in concert with
other pathways involving endoplasmic reticulum and oxida-
tive stress [29, 31].
Although the glucose-lowering efficacy of incretin ago-
nists and DPP-4 inhibitors has been shown in animal models
[37–39], it is worth noting that chronic treatment of db/db
mice with incretin agonists or DPP-4 inhibitors alone only
delays the onset of diabetes at the early stages of disease
progression [40]. Exendin-4 treatment does not prevent the
ongoing deterioration of glucose intolerance in severely
diabetic db/db mice [41]. Likewise, clinical evidence shows
that the efficacy of incretin-based drugs for the treatment of
type 2 diabetes is variable, and may be affected by various
factors such as age [42], stage and severity of diabetes,
differences in responsiveness to GLP-1 in diverse ethnic
groups, genetic variance of GIPR and GLP1R [43, 44], as
well as hyperglycaemia [27]. The current study demon-
strates for the first time that hyperlipidaemia should be
included as a contributing factor to the reduced efficacy of
incretin-based drugs in mouse models of diabetes.
Hyperlipidaemia is closely associated with type 2 diabe-
tes, and glucose-lowering drugs such as thiazolidinediones
and metformin improve glucose and lipid metabolism [45].
Our in vitro data show that elevated NEFA is sufficient to
cause impaired GLP1R signalling, prompting us to test the
relationship between hyperlipidaemia and the efficacy of
incretin-based therapy in animal models of diabetes. The
lipid-lowering agent bezafibrate significantly improved the
serum lipid profile, without affecting blood glucose levels in
db/db mice. Strikingly, after lipid lowering, the DPP-4 in-
hibitor des-fluoro-sitagliptin and the GLP1R agonist
exendin-4 both had a more robust effect on glycaemic
control than co-treatment with vehicle or treatment with
each agent alone. The effects were not due to increases in
insulin sensitivity. Rather the improved glucose tolerance
was associated with restoration of normal islet morphology
and increased beta cell mass. This effect was only apparent
with prolonged incretin activation, since the lowering of
fatty acids did not enhance glucose disappearance after
acute treatment of db/db mice with exendin-4. These results
suggest that the improved glucose homeostasis induced by
chronic administration of exendin-4 and bezafibrate to db/
db mice is effected via long-term improvements in beta cell
mass and function, which may be due to restored expression
of Glp1r and thus GLP1R signalling after lipid lowering.
However, although Gipr expression was also partially re-
stored by bezafibrate treatment, the GIPR agonist D-GIP did
not improve glucose metabolism. Recent reports have dem-
onstrated that GLP1R signalling exerts more robust control
of beta cell survival and regeneration than does GIPR sig-
nalling in mice [46]. It has also been reported that GLP-1-
stimulated p-CREB plays important roles in the regulation
of beta cell survival through GLP1R activation [33]. In this
study, we only observed reduced GLP-1-stimulated p-
CREB during in vitro palmitate treatment. Moreover, only
combined treatment with exendin-4 plus bezafibrate im-
proved islet morphology and increased beta cell mass, as-
sociated with increased beta cell proliferation in db/db mice.
On the other hand, it has been reported that GIP was asso-
ciated with impaired insulin sensitivity [38, 47], and this
may partially explain the differences in efficacy of the
incretin receptor agonists.
The peroxisome proliferator-activated receptor (PPAR)-α
agonist WY14643 has been reported to increase Gipr ex-
pression [48]; at the same time, PPAR-α activation is asso-
ciated with improved beta cell survival and function through
reduction of lipid accumulation by increased fatty acid ox-
idation in beta cells and human islets [49, 50]. It has also
been reported that metformin increases Glp1r expression in
INS-1 cells via a PPAR-α-dependent pathway [51]. Our
results demonstrate that palmitate downregulates GLP1R
in insulinoma cell lines and bezafibrate can improve the
efficacy of des-fluoro-sitagliptin and exendin-4 in mouse
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models of diabetes. Intriguingly, the related nuclear receptor
PPAR-γ has been reported to regulate Gipr expression by
binding to the PPAR response elements within the rat Gipr
promoter [52]. The question of whether PPAR-α activation
regulates incretin receptors in beta cells through direct bind-
ing or indirect improvement in lipotoxicity requires further
investigation.
In summary, our results show that hyperlipidaemia con-
tributes to impaired beta cell responsiveness to GLP-1,
partially through downregulation of GLP1R. Combined
treatment with incretin-based drugs (des-fluoro-sitagliptin
or exendin-4) and lipid-lowering drugs (bezafibrate) results
in synergistic improvements of glucose metabolism and islet
morphology and function. These findings reinforce the im-
portance of lipid management in type 2 diabetes and provide
important information for the design of new incretin-based
therapies for the treatment of type 2 diabetes mellitus.
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